Adell Harriman & Carpenter Inc. Invests $202,000 in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Adell Harriman & Carpenter Inc. purchased a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the fourth quarter, Holdings Channel reports. The fund purchased 600 shares of the medical equipment provider’s stock, valued at approximately $202,000.

A number of other large investors have also added to or reduced their stakes in ISRG. Portside Wealth Group LLC boosted its holdings in Intuitive Surgical by 8.2% in the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after acquiring an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Intuitive Surgical by 58.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after buying an additional 3,054 shares during the period. Kades & Cheifetz LLC bought a new stake in Intuitive Surgical during the fourth quarter valued at $230,000. Blair William & Co. IL grew its holdings in Intuitive Surgical by 3.1% during the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock worth $110,302,000 after acquiring an additional 11,400 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in shares of Intuitive Surgical by 21.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock worth $216,140,000 after acquiring an additional 129,194 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares of the company’s stock, valued at $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The disclosure for this sale can be found here. Insiders have sold a total of 225,093 shares of company stock valued at $87,153,299 in the last ninety days. Company insiders own 0.80% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ISRG. Robert W. Baird reduced their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. Royal Bank of Canada raised their target price on Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. BTIG Research increased their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a report on Friday, April 19th. Citigroup increased their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Mizuho lifted their price target on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Trading Down 0.7 %

Shares of ISRG stock traded down $2.50 during trading hours on Tuesday, reaching $371.64. 129,520 shares of the stock were exchanged, compared to its average volume of 1,631,697. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76. The firm has a market capitalization of $131.82 billion, a price-to-earnings ratio of 67.53, a price-to-earnings-growth ratio of 4.85 and a beta of 1.36. The company’s 50-day moving average price is $386.10 and its 200-day moving average price is $347.50.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.00 earnings per share. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.